Equities

Sichuan Biokin Pharmaceutical Co Ltd

688506:SHH

Sichuan Biokin Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)195.32
  • Today's Change-5.59 / -2.78%
  • Shares traded1.37m
  • 1 Year change+82.54%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments3921,001154
Total Receivables, Net173287162
Total Inventory14110182
Prepaid expenses583323
Other current assets, total124.052.16
Total current assets7761,426424
Property, plant & equipment, net535420405
Goodwill, net------
Intangibles, net283031
Long term investments1.591.842.09
Note receivable - long term------
Other long term assets------
Total assets1,4251,991951
LIABILITIES
Accounts payable30818573
Accrued expenses146200127
Notes payable/short-term debt319181183
Current portion long-term debt/capital leases179375.21
Other current liabilities, total10213483
Total current liabilities1,054737471
Total long term debt193293101
Total debt691511290
Deferred income tax------
Minority interest------
Other liabilities, total272747
Total liabilities1,2731,057620
SHAREHOLDERS EQUITY
Common stock401401361
Additional paid-in capital85985914
Retained earnings (accumulated deficit)(1109)(328)(46)
Treasury stock - common------
Unrealized gain (loss)(0.31)----
Other equity, total1.442.792.76
Total equity152934332
Total liabilities & shareholders' equity1,4251,991951
Total common shares outstanding401401401
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.